Wednesday, July 08, 2015 10:38:02 AM
Recent SNGX News
- Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024 • PR Newswire (US) • 09/16/2024 11:30:00 AM
- Soligenix Receives European Patent for Improved Production of Synthetic Hypericin • PR Newswire (US) • 09/03/2024 11:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/16/2024 08:19:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:13:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/09/2024 08:09:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/09/2024 08:07:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:05:32 PM
- Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results • PR Newswire (US) • 08/09/2024 11:30:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/05/2024 04:15:07 AM
- Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone • GlobeNewswire Inc. • 08/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 11:30:14 AM
- PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results • GlobeNewswire Inc. • 07/15/2024 02:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 05:28:54 PM
- Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma • PR Newswire (US) • 07/09/2024 11:30:00 AM
- Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma • PR Newswire (US) • 06/25/2024 11:30:00 AM
- A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference • PR Newswire (US) • 06/14/2024 11:30:00 AM
- Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial • GlobeNewswire Inc. • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 12:00:25 PM
- Soligenix Announces Reverse Stock Split • PR Newswire (US) • 05/31/2024 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/29/2024 08:05:07 PM
- Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting • PR Newswire (US) • 05/29/2024 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/28/2024 08:08:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:05:27 PM
- Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting • PR Newswire (US) • 05/24/2024 11:30:00 AM
- Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split • PR Newswire (US) • 05/23/2024 11:30:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM